MedTrace Logo

Safety of the CO-rebreathing Method in Stable Coronary Artery Disease and COPD Patients

NCT01470274 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2016-07-29

No results posted yet for this study

Summary

The primary objective is to establish the safety of the CO-rebreathing method for measuring total blood and plasma volume in CAD patients. The working hypothesis is that the CO-rebreathing method is safe in use with coronary artery disease patients and that it does not cause myocardial ischemia or cardiovascular damage.

Conditions

Sponsors & Collaborators

  • Norwegian University of Science and Technology

    lead OTHER

Principal Investigators

  • Trine Karlsen, PhD · Norwegian University of Science and Technology

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-01-31
Completion
2012-02-29

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01470274 on ClinicalTrials.gov